Midsona

Midsona

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Midsona - Looking due North as South comps ease in H2

19 juli 2026

  • Q2'26: Profitable but not yet growing into the story
  • H2'26e: One tailwind balanced with a few open cost questions
  • Trading at NTM EV/EBITA of 9x

North Europe is the underlying culprit

Q2 missed the mark on both sales and adj. EBIT, although not by a lot (-2% on sales, -7% on adj. EBIT, i.e. SEK 1m). The gross margin was in line with expectations at 29%, but elevated opex caused the EBIT miss. Management flags that it has stepped up the marketing behind priority brands. The Nordics impressed (adj. EBIT 15% above ABGSCe), while North Europe stayed flat at SEK 5m adj. EBIT on a further -4% organic sales decline. South Europe, meanwhile, improved to SEK 2m from break-even despite a -7% organic drag from the Spanish fire aftermath.

The Spain comp fades, but input cost risk doesn't

The clearest structural tailwind heading into H2 2026 is the phasing out of the Spain fire base effect in Q3, which should remove a significant drag on contract manufacturing comparisons. Cost savings are fully embedded in the run rate, but marketing spend will remain elevated as a strategic choice. Raw material and energy cost trends for H2 remain uncertain, with some risk to input costs from Middle East disruptions and fertiliser price increases. The outlook comments in the report are fairly in line with our previous understanding, with nothing in the report warranting a material change to our estimates or long-term view.

We cut '26e adj. EBITA by 2%

We make slight cuts to our sales and adj. EBITA estimates, lowering '26e-'27e sales by ~1% p.a. and adj. EBITA by 2-1%, respectively. We slightly lower our H2'26 estimates to reflect a somewhat elevated opex base. Our EPS estimates are up on lower-than-expected net financials and taxes. Based on our revised estimates, the company is trading at ~9x NTM EV/EBITA, which is ~15% below current peer multiples. We note that peers are in turn trading ~20% below their 10-year historical median of ~14x NTM EV/EBITA.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys
2026-08-21 Generic - Investing while growing Generic Analys
2026-08-21 Impact Coatings - A quarter driven by Coating Ser... Impact Coat.. Analys
2026-08-21 Skolon - Sweden profitability gains continue Skolon Analys
2026-08-21 I-tech - Strongest quarter on record I-tech Analys
2026-08-20 Tempest Security - Patrols below plan Tempest Sec.. Analys
2026-08-20 Tempest Security - Progress made but expectations... Tempest Sec.. Analys
2026-08-20 Ascelia Pharma - Still alive: Fighting to reverse... Ascelia Pharma Analys
2026-08-20 Clavister - Defence drives record quarter Clavister Analys
2026-08-20 Catella - Q2 softer than expected, but underlying... Catella Analys
2026-08-20 Generic - Volumes continue to grow Generic Analys
2026-08-19 SinterCast - Past the trough, but recovery pace u... SinterCast Analys
2026-08-19 Xplora Technologies - EBITDA -13% on soft senior ... Xplora Tech.. Analys